Kathryn Haviland
Chief Executive Officer presso BLUEPRINT MEDICINES CORPORATION
Patrimonio netto: 14 M $ in data 29/02/2024
Profilo
Kathryn Haviland è nel consiglio di Fulcrum Therapeutics, Inc. e direttore operativo di Blueprint Medicines Corp., membro della Harvard Business School Health Industry Alumni Association e membro del Biopharma Executive Council. La sig.ra Haviland ha occupato in precedenza la posizione di vicepresidente delle malattie rare presso Idera Pharmaceuticals, Inc., responsabile dello sviluppo commerciale presso Sarepta Therapeutics, Inc. e direttore esecutivo dello sviluppo commerciale presso PTC Therapeutics, Inc. Si è laureata alla Wesleyan University e ha conseguito un MBA alla Harvard Business School.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
07/03/2024 | 153 177 ( 0.25% ) | 14 M $ | 29/02/2024 | |
27/06/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Posizioni attive di Kathryn Haviland
Società | Posizione | Inizio |
---|---|---|
BLUEPRINT MEDICINES CORPORATION | Chief Executive Officer | 04/04/2022 |
FULCRUM THERAPEUTICS, INC. | Chairman | 10/01/2022 |
Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Corporate Officer/Principal | - |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Director/Board Member | 16/10/2023 |
Precedenti posizioni note di Kathryn Haviland
Società | Posizione | Fine |
---|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01/12/2015 |
SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2014 |
PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2012 |
Formazione di Kathryn Haviland
Wesleyan University | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
SAREPTA THERAPEUTICS, INC. | Health Technology |
PTC THERAPEUTICS, INC. | Health Technology |
BLUEPRINT MEDICINES CORPORATION | Health Technology |
FULCRUM THERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Harvard Business School Health Industry Alumni Association | |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Commercial Services |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |